Marché des anticorps monoclonaux – Analyse des tendances et de la croissance | Année de prévision 2031

  • Report Code : TIPRE00026641
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 163
Buy Now

Le marché des anticorps monoclonaux devrait atteindre 243,05 milliards de dollars américains d'ici 2028, contre 111,01 milliards de dollars américains en 2021 ; il devrait croître à un TCAC de 11,8 % de 2021 à 2028.



La prévalence croissante du cancer et d'autres maladies chroniques, et une augmentation considérable des cas de COVID-19 dans divers Les régions sont les principaux facteurs qui alimentent la croissance du marché. Selon le World Cancer Research Fund et l'American Institute for Cancer, en 2020, ~18,1 millions de cas de cancer ont été enregistrés, dont 9,3 millions de cas chez les hommes et 8,8 millions de cas chez les femmes. L'utilisation d'anticorps monoclonaux dans le traitement de divers types de cancer est encore en phases 2 et 3.



Introduction stratégique



L'Amérique du Nord devrait continuer à dominer le marché des anticorps monoclonaux au cours de la période 2021-2028. Les États-Unis détiennent la plus grande part du marché dans cette région et devraient continuer d'être un actionnaire dominant sur le marché au cours de la période de prévision. Selon les statistiques publiées par Globocan 2020, ~1 806 590 nouveaux cas de cancer ont été diagnostiqués aux États-Unis et ~606 520 personnes sont décédées des suites de cette maladie. Selon un rapport du Département américain du commerce, son Institut national des normes et de la technologie (NIST) a annoncé le financement de 153 millions de dollars américains à l'Institut national pour l'innovation dans la fabrication de produits biopharmaceutiques. De plus, la FDA a étendu son soutien au développement d'anticorps monoclonaux pendant la prévalence du COVID-19.



Régions lucratives pour le marché des anticorps monoclonaux



< h3>Aperçu du marché

L'augmentation significative de la prévalence du cancer et d'autres maladies chroniques stimule la croissance du marché



Selon le rapport de l'American Cancer Society , ~ 16,9 millions de personnes ayant des antécédents de cancer résidaient aux États-Unis en janvier 2019. D'ici janvier 2030, la population de survivants du cancer devrait atteindre 22,1 millions en raison de la croissance et du vieillissement de la population uniquement. Par conséquent, avec la prévalence croissante du cancer et d'autres maladies chroniques, la demande de produits biologiques, tels que les anticorps monoclonaux (mAB), a également augmenté. En tant que composants principaux de nombreux schémas thérapeutiques et traitements rentables, les produits biologiques jouent un rôle clé dans le traitement du cancer.



Informations basées sur la source



< p> En fonction de la source, le marché des anticorps monoclonaux est segmenté en murin, chimérique, humain et humanisé. On estime que le segment humain représente la plus grande part de marché au cours de la période 2021-2028. La croissance du marché de ce segment est attribuée à la hausse due à l'intégration d'anticorps monoclonaux humains pour le traitement de divers types de maladies infectieuses. Par exemple, Regeneron a lancé ensemble le casirivimab et l'imdevimab, un cocktail d'anticorps approuvé par la FDA, pour une utilisation dans le COVID-19. Le médicament a reçu l'autorisation d'utilisation d'urgence (EUA) de la FDA. Il est utilisé pour le traitement du COVID-19 léger à modéré chez les adultes ainsi que chez les patients pédiatriques âgés d'au moins 12 ans et pesant au moins 40 kg. De plus, une augmentation de leur utilisation dans diverses maladies chroniques et l'utilisation de technologies avancées de génie génétique sont parmi les facteurs importants qui stimulent la croissance du segment de marché.



Marché des anticorps monoclonaux, par source - 2020 et 2028



Indication-Based Insights



Basé sur l'indication, le cancer, les maladies auto-immunes, les maladies inflammatoires, les maladies infectieuses, les maladies microbiennes, et d'autres. Le segment du cancer allait dominer le marché dans les années à venir. Les progrès liés à l'application thérapeutique des anticorps monoclonaux ont permis leur mise en œuvre réussie dans les traitements de divers types de cancer, tels que le cancer du sein, le cancer du poumon et le cancer du côlon. Les médicaments basés sur ces anticorps aident à signaler les cellules cancéreuses, à déclencher la destruction de la membrane cellulaire, à bloquer les inhibiteurs du système immunitaire, etc. La FDA, en juin 2020, a approuvé deux médicaments - l'olaparib et le rucaparib pour le traitement du cancer de la prostate. Le médicament est particulièrement efficace chez les hommes atteints d'un cancer de la prostate qui s'est propagé ou métastasé et qui a cessé de répondre aux traitements hormonaux standard, c'est-à-dire une maladie résistante à la castration.



Utilisateur final- Aperçus basés



Par utilisateur final, le marché des anticorps monoclonaux est segmenté en hôpitaux, instituts de recherche et autres. Le segment hospitalier détient la plus grande part de marché en raison de l'adoption croissante des mAB comme ligne de traitement privilégiée, en particulier pour le traitement du cancer.





< p>Les entreprises opérant sur le marché des anticorps monoclonaux adoptent la stratégie d'innovation de produits pour répondre à l'évolution des demandes des clients à travers le monde, ce qui leur permet également de maintenir leur marque sur le marché mondial.



Marché des anticorps monoclonaux - Segmentation



En fonction de la source, le marché des anticorps monoclonaux est segmenté en humains, humanisés, chimériques et murins. Par méthode de production, le marché est segmenté en in-vitro et in-vivo. Le marché des anticorps monoclonaux, par indication, est en outre segmenté en cancer, maladies auto-immunes, maladies infectieuses, maladies inflammatoires, maladies microbiennes et autres. Par application, le marché est subdivisé en applications thérapeutiques, applications de diagnostic et applications de recherche. En outre, en fonction de l'utilisateur final, le marché est segmenté en hôpitaux, autres et instituts de recherche.



Marché des anticorps monoclonaux - par géographie



  1. Amérique du Nord

    1. États-Unis

    2. Canada

    3. Mexique



  2. Europe

    1. France

    2. Allemagne

    3. Italie

    4. Royaume-Uni

    5. Espagne

    6. Reste de l'Europe




  3. Asie-Pacifique (APAC)

    1. Chine

    2. Inde

    3. < li>Corée du Sud
    4. Japon

    5. Australie

    6. Reste de l'APAC




  4. Moyen-Orient et Afrique (MEA)

    1. Afrique du Sud

    2. Arabie saoudite

    3. EAU

    4. Reste de MEA




  5. Sud et centre Amérique (SCAM)

    1. Brésil

    2. Argentine

    3. Reste de SCAM

    < TIP>



Profils d'entreprise




  1. Novartis AG
  2. Pfizer Inc.

  3. GlaxoSmithKline plc

  4. Amgen, Inc

  5. Daiichi Sankyo Company, Limité

  6. F. Hoffmann-La Roche AG

  7. AstraZeneca

  8. Elli Lily and Company

  9. Bayer AG

  10. < li>Société Bristol-Myers Squibb






Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the regional market scenario of the monoclonal antibodies market?

Global monoclonal antibodies market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for monoclonal antibodies market. The US is estimated to hold the largest share in the monoclonal antibodies market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for monoclonal antibodies accounting fastest growth of the region during the coming years.

Who are the key players in the monoclonal antibodies market?

Novartis AG, Pfizer, Inc., GlaxoSmithKline Plc, Amgen, Inc., Daiichi Sankyo Company, Limited, F.Hoffmann-La Roche AG, AstraZeneca, Elli Lilly and Company, Bayer AG, Bristol-Myers Squibb Company are among the leading companies operating in the global monoclonal antibodies market

Which production method segment held the largest revenue (US$ Mn) in the monoclonal antibodies market?

The in vitro segment dominated the global monoclonal antibodies market and accounted for the largest revenue of 75,044.50 Mn in 2021.

What is meant by the monoclonal antibodies market?

Food and Drug Administration (FDA) defines monoclonal antibodies as immunoglobulin molecules that are secreted from a population of identical cells. They are homogenous in structure and binding specificity. These are used as multifunctional components for the immune system. They facilitate numerous cellular and humoral reactions to a variety of antigens, which include host and foreign substances.

What are the driving factors for the monoclonal antibodies market across the globe?

Significant rise in the cancer and chronic diseases is one of the most significant factors responsible for the overall market growth.

Which segment led the monoclonal antibodies market?

Based on source, human segment took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.

The List of Companies - Monoclonal Antibody Market

  1. Novartis AG
  2. Pfizer Inc.
  3. GlaxoSmithKline plc
  4. Amgen, Inc
  5. Daiichi Sankyo Company, Limited
  6. F. Hoffmann-La Roche AG
  7. AstraZeneca
  8. Elli Lilly and Company
  9. Bayer AG
  10. Bristol-Myers Squibb Company

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports